Clinical Trial

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-24; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-04-21
Trial Details
NCT Number NCT06905873
Lead Sponsor Forte Biosciences, Inc.
Conditions Vitiligo
Enrollment 64 participants
Start Date 2025-03-25
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-20